Optomed Oyj

Optomed Plc has registered 1,500,000 new shares from its directed share issue in the Finnish Trade Register as of July 1, 2024. This brings the total number of shares to 19,630,397, including 353,973 treasury shares. The new shares are eligible for dividends and other shareholder rights from the registration date and will be traded on Nasdaq Helsinki Ltd starting today. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software for diagnosing eye diseases. For further information, contact CFO Sakari Knuutti at sakari.knuutti@optomed.com.

Optomed Plc has successfully completed a directed share issue, raising approximately EUR 7.9 million. The Board of Directors decided to issue up to 1,500,000 new shares to a limited number of Finnish and international institutional and qualified investors, deviating from pre-emptive subscription rights. The share issue also involved certain current shareholders to ensure its success. The subscription price was EUR 5.25 per share, representing a 13.8% discount from the closing price on 26 June 2024. The funds will support Optomed's new AI initiatives and US commercialization activities. The new shares will be registered in the Finnish Trade Register and are expected to begin trading on Nasdaq Helsinki Ltd on or about 1 July 2024. This share issue aligns with the company's strategy to rapidly develop its business and utilize its market position in the digitalization and AI transformation of the medical and health-related sector.

Optomed Plc has entered into a shareholder's agreement with Zhongbao Fund to establish a joint venture in China, focusing on eye screening services. Optomed will hold 19.9% of the joint venture, while Zhongbao will own 80.1%. This venture aligns with China's strategic plan to promote nationwide eye screening services, addressing the growing challenge of an aging population and a high number of undiagnosed diabetic patients. The cooperation will start with a trial period in collaboration with a leading ophthalmic institute under the National Health Commission of China. Additionally, Optomed has increased its credit risk accrual from 50% to 75% for a receivable of EUR 1,556,000 from a Chinese client due to late repayments. The establishment of the joint venture does not impact the company's outlook, and Optomed expects its full-year 2024 revenue to grow compared to 2023. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and screening software, with operations in Finland, the US, and China, and sales in over 60 countries.

On 22nd May 2024, Optomed Plc announced a transaction involving Laura Piila, a senior manager at the company. The transaction involved the acceptance of a stock option linked to a share or a debt instrument named 2024A. The volume of the transaction was 35,000 units, with a unit price and volume weighted average price of 0.00 EUR. This was an initial notification, and no transaction venue was applicable.

On 22 May 2024, Markku Myllylä, a senior manager at Optomed Plc, accepted a stock option linked to a share or a debt instrument named 2024A. The transaction, which was part of a stock option programme, involved 2,500 units at a unit price of 0.00 EUR. The volume-weighted average price was also 0.00 EUR.

The Annual General Meeting (AGM) of Optomed Plc, held on 10 May 2024, adopted the financial statements for 2023 and confirmed the Board of Directors’ decision not to pay a dividend for that year. The AGM also re-elected the six members of the Board of Directors, confirmed the annual Board remuneration, and re-elected KPMG Oy Ab as the company's auditor. Changes were made to the terms of the Stock Option Plans, extending the subscription periods for shares under each plan to end on 31 December 2027. The AGM also authorized the Board to repurchase Optomed’s own shares and to issue shares and other special rights. At a subsequent meeting, the Board elected Petri Salonen as its Chairman.

Optomed Plc has announced its Annual General Meeting (AGM) to be held on 10 May 2024. Shareholders registered by 26 April 2024 are eligible to attend the meeting. The AGM will discuss matters including the adoption of financial statements, the use of profit shown on the balance sheet, the discharge of the board of directors and CEO from liability, and the remuneration policy for governing bodies. The board proposes no dividend to be paid for the financial period of 1 January – 31 December 2023 due to a loss in that period. The board also proposes the adoption of the remuneration report and policy for governing bodies, with no material changes suggested. The AGM will also consider the re-election of current board members, the remuneration of the auditor, and amendments to the terms of stock option plans. Shareholders can vote in advance, with instructions provided in the notice.